Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy

Virology

Volumn 396, Issue 2, 2010, Pages 280-288

  Simmons, Monika ^a   Burgess, Timothy ^a   Lynch, Julia ^b   Putnak, Robert ^b  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Dengue DNA; Live attenuated virus; Prime boost; Purified inactivated virus

Indexed keywords

DENGUE VACCINE; DNA VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEROTYPE; VACCINATION; VIREMIA; VIRUS INACTIVATION;

ANIMALS; ANTIBODY FORMATION; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, SECONDARY; MACACA MULATTA; VACCINES, ATTENUATED; VIREMIA;

ANIMALIA; DENGUE VIRUS; MACACA MULATTA;

EID: 70749109995     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.10.023     Document Type: Article

References (30)

1. Barnett S.W., Rajasekar S., Legg H., Doe B., Fuller D.H., Hayens J.R., Walker C.M., and Steimer K.S. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp 120 protein subunit. Vaccine 15 8 (1997) 869-873
2. Bancroft W.H., Top Jr. F.H., Eckels K.H., Anderson Jr. J.H., McCown J.M., and Russell P.K. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients. Infect. Immun. 31 2 (1981) 698-703
3. Bhamarapravati N., and Yoksan S. Live-attenuated tetravalent dengue vaccine. In: Gubler D.J., and Kuno G. (Eds). Dengue and Dengue Hemorrhagic fever (1997), CAB International, Cambridge, United Kingdom 367-377
4. Durbin A.P., McArthur J., Marron J.A., Blaney Jr. J.E., Thumar B., Wanionek K., Murphy B.R., and Whitehead S.S. The live-attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum. Vaccine 2 4 (2006) 167-173 Jul-Aug
5. Durbin A.P., McArthur J.H., Marron J.A., Blaney Jr. J.E., Thumar B., Wanionek K., Murphy B.R., and Whitehead S.S. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy adult volunteers. Hum. Vaccin. 2 6 (2006) 255-260 Nov-Dec
6. Eckels K.H., Dubois D.R., Putnak R., Vaughn D.W., Innis B.L., Henchal E.A., and Hoke Jr. C.H. Modification of dengue virus strain by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am. J. Trop. Med. Hyg. 69 6 Suppl (2003) 12-16 Dec Erratum in: Am. J. Trop. Med. Hyg. 2004. Mar: 70(3):336
7. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., Yoksan S., Duan X., Ermak T.H., Kanesa-Thasan N., Bedford P., Lang J., Quentin-Millet M.J., and Monath T.P. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase 1 clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin. 2 2 (2006) 60-67 Mar-Apr
8. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., Jourdier T.M., Ramirez L., Gregoire V., Charnay C., Burdin N., Dumas R., and Lang J. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg. 80 2 (2009) 302-311 Feb
9. Halstead S.B. Pathogenesis of dengue: challenges to molecular biology. Science 239 4839 (1988) 476-481 Jan 29
10. Halstead S.B., and Marchette N.J. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am. J. Trop. Med. Hyg. 69 6 Suppl (2003) 5-11 Dec
11. Huang C.Y., Butrapet S., Tsuchiya K.R., Bhamarapravati N., Gubler D.J., and Kinney R.M. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J. Virol. 77 21 (2003) 11436-11447 Nov
12. Kanesa-Thasan N., Sun W., Ludwig G.V., Rossi C., Putnak J.R., Mangiafico J.A., Innis B.L., and Edelman R. Atypical antibody responses in dengue vaccine recipients. Am. J. Trop. Med. Hyg. 69 6 Suppl (2003) 32-38 Dec Erratum in: Am. J. Trop. Med. Hyg. 2004. Mar:70(3):336
13. Kaufman B.M., Summers P.L., Dubois D.R., and Eckels K.H. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36 2 (1987) 427-434 Mar
14. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., and Saluzzo J.F. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24 9 (2006) 1238-1241 Feb:27 Epub. 2005. Sep 23
15. Kochel T., Wu S.J., Raviprakash K., Hobart P., Hoffman S., Porter K., and Hayes C. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 15 5 (1997) 547-552 Apr
16. McArthur J.H., Durbin A.P., Marron J.A., Wanionek K.A., Thumar B., Pierro D.J., Schmidt A.C., Blaney Jr. J.E., Murphy B.R., and Whitehead S.S. Phase 1 clinical evaluation of rDEN4Delta30-200, 201. a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am. J. Trop. Med. Hyg. 79 5 (2008) 678-684 Nov
17. Monath T.P. Pathology of the flaviviruses. In: Schlesinger S., and Schlesinger M.J. (Eds). The Togaviridae and Flaviviridae (1986), Plenum, New York 375-440
18. Putnak R., Barvir D., Burrous J., Dubois D., Dandrea V., Hoke C., Sadoff J., and Eckels K. Development of a purified, inactivated dengue 2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis. 174 (1996) 1176-1184
19. Putnak J.R., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., Bignami G., Houng H.S., Chen R.C., Barvir D.A., Seriwatana J., Cayphas S., Garcon N., Gheysen D., Kanesa-Thasan N., McDonell M., Humphreys T., Eckels K.H., Prieels J.P., and Innis B.L. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23 35 (2005) 4442-4452 Aug 15
20. Raviprakash K., Marques E., Ewing D., Lu Y., Phillips I., Porter K.R., Kochel T.J., August T.J., Hayes C.G., and Murphy G.S. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology 290 1 (2001) 74-82 Nov 10
21. Raviprakash K., Ewing D., Simmons M., Porter K.R., Jones T.R., Hayes C.G., Stout R., and Murphy G.S. Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315 2 (2003) 345-352 Oct 25
22. Russell P.K., Nisalak A., Sukhavachana P., and Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J. Immunol. 99 2 (1967) 285-290
23. Sabchareon A., Lang J., Chantavanich P., Yoksan S., Forrat R., Attanath P., Sirivichayakul C., Pengsaa K., Pojjaroen-anant C., Chokejindachai W., Jagsudee A., Saluzzo J., and Bhamarapravati N. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio and multiple doses. Am. J. Trop. Med. Hyg. 66 3 (2002) 264-272
24. Scott R.M., Eckels K.H., Bancroft W.H., Summer P.L., McCown J.M., Anderson J.H., and Russell P.K. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status. J. Infect. Dis. 148 6 (1983) 1055-1060
25. Sedegah M., Jones T.R., Kaur M., Hedstrom R., Hobart P., Tine J.A., and Hoffman S.L. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. 95 (1998) 7648-7653
26. Simmons M., Murphy G.S., Kochel T., Raviprakash K., and Hayes C.G. Characterization of antibody responses to combinations of a dengue-2DNA and dengue-2 recombinant subunit vaccine. Am. J. Trop. Med. Hyg. 65 5 (2001) 420-426
27. Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., and Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J. Virol. 80 19 (2006) 9577-9585
28. Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., Houng H.S., Tang D., Scherer J.M., Hoke Jr. C.H., and Innis B.L. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69 6 Suppl. (2003) 24-31 Dec
29. Sun W., Nisalak A., Gettayacamin M., Eckels K.H., Putnak J.R., Vaughn D.W., Innis B.L., Thomas S.J., and Endy T.P. Protection of rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J. Infect. Dis. 193 12 (2006) 1658-1665 Jun 15
30. Sun W., Cunningham D., Wasserman S.S., Perry J., Putnak J.R., Eckels K.H., Vaughn D.W., Thomas S.J., Kanesa-Thasan N., innis B.L., and Edelman R. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum. Vaccine 5 1 (2009) 33-40 Jan-Feb